Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03636412 · ClinicalTrials.gov registry record · NA

Improving Frailty With a Rigorous Ambulation Intervention in Lung Transplant Patients

A NA study of Sarcopenia and Mobility Limitation, sponsored by The Cleveland Clinic.

Completed
Registry status
NA
Development phase
200
Enrollment target
1
Study location

NCT03636412: Completed NA study of Sarcopenia and Mobility Limitation, sponsored by The Cleveland Clinic.

NCT03636412 is a NA study of Sarcopenia and Mobility Limitation that has completed, run by The Cleveland Clinic. The registered enrollment target is 200 participants, above the 76-participant average among 41 other Sarcopenia trials with a reported enrollment target (163% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03636412, a NA study of Sarcopenia and Mobility Limitation, has completed, sponsored by The Cleveland Clinic.

COMPLETED
Registry status
NA
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to assess the feasibility and effectiveness of dedicated ambulator-assisted physical activity in lung transplant inpatients. The primary hypothesis is that an ambulator-assisted intervention for lung transplant patients will prove feasible and may result in improved frailty, hospital outcomes, including less need for inpatient rehabilitation and shorter length of stay in the hospital.

Primary Outcome

The duration of time in days for the index admission for the patient beginning immediately after lung transplant

Interventions

  • OTHER Ambulation

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2018-08-15
Est. Completion 2024-12-31
Phase NA
The Cleveland Clinic

688 total trials

What the finished NCT03636412 record still lists

NCT03636412 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 76-participant average among 41 other Sarcopenia trials with a reported enrollment target (163% higher).

The record links to 5 conditions, with Sarcopenia appearing as the primary indexed condition, and to 1 intervention - of which Ambulation is the first listed.

NCT03636412 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT03636412 about?

NCT03636412 is a clinical study titled "Improving Frailty With a Rigorous Ambulation Intervention in Lung Transplant Patients". The objective of this study is to assess the feasibility and effectiveness of dedicated ambulator-assisted physical activity in lung transplant inpatients. The primary hypothesis is that an ambulator-assisted intervention for lung transplant patients will prove feasible and may result in improved fr...

What is the current status of trial NCT03636412?

This trial is currently completed. It is a NA study. The enrollment target is 200 participants. The study started on 2018-08-15. Estimated completion is 2024-12-31.

What conditions does trial NCT03636412 study?

This clinical trial studies the following conditions: Sarcopenia, Mobility Limitation, Transplant-Related Disorder, Frail Elderly Syndrome, Lung Graft Dysfunction.

What interventions are being tested in trial NCT03636412?

The interventions under investigation include: Ambulation (OTHER).

Who is sponsoring clinical trial NCT03636412?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03636412 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sarcopenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03636412's enrollment target sits among peer trials

200 4th of 41 higher than 37 of 41 other Sarcopenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sarcopenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03636412, the US trial registry maintained by the National Library of Medicine. NCT03636412 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.